ArticleObstetrics & gynecology science2026
Dual effects of anti-Müllerian hormone on ovarian response and fertilization in assisted reproductive technology cycles: a retrospective cohort study.
Article in Obstetrics & gynecology science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Objective: To investigate the dual effects of anti-Müllerian hormone (AMH) on ovarian response, fertilization outcomes, and clinical pregnancy in assisted reproductive technology (ART) cycles. Methods: This retrospective cohort study screened 6,312 in vitro fertilization or intracytoplasmic sperm injection cycles performed between 2018 and 2023. After excluding cycles with missing AMH or body mass index (BMI) values, non-ART cycles, and extreme BMI values (<18 or ≥45 kg/m2), 4,399 cycles were included. AMH level, age, and BMI were evaluated as independent variables. Ovarian response (retrieved oocyte count) and normally fertilized embryos (two pronuclei) were analyzed using multivariable linear regression and clinical pregnancy was evaluated using logistic regression. Results: AMH level showed a strong positive association with ovarian response (β=2.348; P<0.001), whereas age showed a significant negative association. After adjusting for age, BMI, fertilization method, and retrieved oocytes, AMH level showed a small but significant negative association with fertilized embryo count (β=-0.044; P=0.027). In the subgroup analysis, cycles with AMH ≥10 ng/mL showed higher oocyte yield but lower fertilization (0.561 vs. 0.694; P<0.001) and clinical pregnancy rates (5.7% vs. 23.10%; P<0.001) than those with AMH <10 ng/mL. Increasing age and AMH levels were independently associated with reduced odds of clinical pregnancy. Conclusion: AMH may reflect ovarian reserve quantity rather than optimal reproductive potential, showing a positive association with oocyte yield, but a negative association with fertilization and clinical pregnancy outcomes in ART cycles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.